1 / 10

Highlights from ASCO 2010

Highlights from ASCO 2010. Tables and figures from selected presentations. MPR versus Tandem MEL200 + ASCT as Consolidation Therapy in NDMM. Induction. Consolidation. NS, not significant. Adapted from Palumbo AP, et al. ASCO 2010. Abstract 8015 (oral presentation).

chava
Télécharger la présentation

Highlights from ASCO 2010

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Highlights from ASCO 2010 Tables and figures from selected presentations

  2. MPR versus Tandem MEL200 + ASCT as Consolidation Therapy in NDMM Induction Consolidation NS, not significant Adapted from Palumbo AP, et al. ASCO 2010. Abstract 8015 (oral presentation).

  3. Meta-analysis of MP vs. MPT Adapted from Waage A, et al. ASCO 2010. Abstract 8130 (poster presentation).

  4. Carfilzomib in R/R MM Adapted from Vij R, et al. ASCO 2010. Abstract 8000 (oral presentation).

  5. New Combinations with Lenalidomide/dex in R/R MM Presented at ASCO 2010 Adapted from Bensinger (abs 8029), Mateos (abs 8030), Richardson (abs 8031), Mahindra (abs 8032), Lonial (abs 8020).

  6. New Combinations with Bortezomib in R/R MM Presented at ASCO 2010 Adapted from San-Miguel (abs 8001), Jakubowiak (abs 8003), Jagannath (abs 8133).

  7. Romidepsin Shown to be Active in All 3 Disease Compartments in CTCL SLD = sum of longest diameter SWAT = severity-weighted assessment tool Adapted from Kim E, et al. ASCO 2010. Abstract 8047 (poster presentation).

  8. Denileukin Diftitox in CTCL CD25+ CD25– Adapted from Duvic M, et al. ASCO 2010. Abstract 8055 (poster presentation).

  9. CALGB 100104: TTP and OS Time to Progression Overall Survival 1.0 1.0 Lenalidomide Lenalidomide Median TTP not reached 0.8 0.8 Placebo 0.6 0.6 Probability Not long enough follow-up to determine difference in OS 0.4 0.4 Placebo Median TTP 25.5 months Lenalidomide arm: 11 deaths Placebo arm: 17 deaths (P < 0.2) 0.2 0.2 0.0 0.0 Median Follow-up from randomization is 12 months 0 1200 200 400 600 800 1000 1400 0 1200 200 400 600 800 1000 1400 Time since ASCT (days) Time since ASCT (days) Adapted from McCarthy PL, et al. ASCO 2010. Abstract 8017 (oral presentation).

  10. Lenalidomide Consolidation and Maintenance following First-line ASCT (3-year PFS) 1.00 Lenalidomide 3-year PFS: 68% 0.75 HR 0.46 P < 10–7 Probability 0.50 Placebo 3-year PFS: 34% 0.25 0.00 0 6 12 18 24 30 36 Months Adapted from Attal M, et al. ASCO 2010. Abstract 8018 (oral presentation).

More Related